Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Bleximenib

Small molecule · Inhibitor of menin (MEN1) · developed by Janssen Research & Development, LLC

Phase 2/3 Most advanced trial
1 Registered trials

What is Bleximenib?

Bleximenib is an orally bioavailable protein-protein interaction inhibitor that disrupts the menin-MLL complex. It reduces expression of downstream target genes and inhibits proliferation of leukemic cells with KMT2A alterations or NPM1 mutations. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
menin (MEN1), mixed-lineage leukemia 1 (KMT2A) (binding partner it blocks), nucleophosmin 1 (NPM1) (biomarker)
Mechanism
Inhibitor of menin (MEN1)
Therapy area
Oncology
Developer
Janssen Research & Development, LLC
In trials of
SNDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
DCN5WEN78T

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03013998 Phase 2/3 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Recruiting SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on MEN1

Revumenib FDA approved

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.